Astrazeneca plc
NASDAQ: AZN
$65.04
-$0.25 (-0.4%)
Closing Price on November 14, 2024
AZN Articles
These five top growth companies are all rated Buy and pay outstanding dividends, and they have good growth prospects.
Published:
Last Updated:
Monday’s top analyst upgrades, downgrades and initiations include AstraZeneca, Dr Pepper Snapple, Fortinet, GrubHub, Jazz Pharmaceutical and Unilever.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include American Water Works, JB Hunt, Ford, General Motors and AstraZeneca.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include Alcoa, American Airlines, Equifax, Mindbody, Tiffany and Tyler Technologies.
Published:
Last Updated:
According to Merrill Lynch, the health care sector should act as a good hedge against volatility. Even biotech was shown to offer growth at a reasonable price.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Thursday include Arch Coal, Editas Medicine, FireEye, Generac, NextEra Energy and Under Armour.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include Ambarella, Apple, Campbell Soup, Gap, Kinross Gold, Lululemon Athletica and Palo Alto Networks.
Published:
Last Updated:
Shares of Pieris Pharmaceuticals saw perhaps one of the biggest gains on Wednesday after the company announced a critical collaboration with AstraZeneca.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Monday include Canada Goose, Cypress Semiconductor, Ralph Lauren, Sunoco, Tesla and Wells Fargo.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen from Friday include AECOM, Apache, Panera, Sunoco and Wal-Mart.
Published:
Last Updated:
Wednesday’s top analyst upgrades, downgrades and initiations included AstraZeneca, Hasbro, Roche, Peabody Energy, Suncor and Wynn Resorts,
Published:
Last Updated:
Valeant Pharmaceuticals received a key FDA approval early on Thursday, but it seems to be a mixed blessing.
Published:
Last Updated:
Although this earnings season has been relatively positive, the Dow has stepped away from its 20,000 mark, and it seems the animal spirits powering this rally might not be as positive as they once...
Published:
Last Updated:
December 7, 2016: Here are four stocks trading with relatively heavy volume among 34 equities making new 52-week lows in Wednesday’s session. On the NYSE, advancers led decliners by more than 3 to...
Published:
Last Updated:
December 2, 2016: Here are four stocks trading with relatively heavy volume among 42 equities making new 52-week lows in Monday’s session. On the NYSE, advancers led decliners by about 2.5 to 1 and...
Published:
Last Updated: